Merck ends the sorry saga of blood cancer drug it got from ArQule
Merck has ended development of a BTK inhibitor that was the main reason it bought ArQule for $2.7 billion in 2019.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Source link







